SFE Investment Counsel’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.23M Sell
19,432
-75
-0.4% -$16.6K 0.67% 59
2025
Q4
$4.46M Sell
19,507
-6,522
-25% -$1.49M 0.68% 57
2025
Q3
$6.03M Sell
26,029
-208
-0.8% -$42.4K 0.96% 39
2025
Q2
$4.87M Buy
26,237
+4,863
+23% +$904K 0.86% 44
2025
Q1
$4.48M Sell
21,374
-6,182
-22% -$1.2M 0.89% 45
2024
Q4
$4.9M Sell
27,556
-3,922
-12% -$721K 1.04% 36
2024
Q3
$6.22M Sell
31,478
-6
-0% -$1.12K 1.29% 28
2024
Q2
$5.4M Sell
31,484
-157
-0.5% -$26K 1.2% 30
2024
Q1
$5.76M Sell
31,641
-628
-2% -$108K 1.31% 25
2023
Q4
$5M Sell
32,269
-400
-1% -$58.3K 1.3% 30
2023
Q3
$4.87M Sell
32,669
-319
-1% -$46.8K 1.42% 25
2023
Q2
$4.44M Sell
32,988
-2,384
-7% -$350K 1.26% 29
2023
Q1
$5.36M Sell
35,372
-1,211
-3% -$185K 1.66% 20
2022
Q4
$5.44M Sell
36,583
-1,771
-5% -$272K 1.69% 18
2022
Q3
$5.15M Sell
38,354
-811
-2% -$116K 1.62% 18
2022
Q2
$6M Sell
39,165
-1,728
-4% -$264K 1.79% 17
2022
Q1
$6.63M Sell
40,893
-6,926
-14% -$1.01M 1.68% 17
2021
Q4
$6.47M Sell
47,819
-29
-0.1% -$3.43K 1.66% 17
2021
Q3
$5.16M Buy
47,848
+1,575
+3% +$180K 1.45% 24
2021
Q2
$5.21M Buy
46,273
+1,337
+3% +$151K 1.43% 27
2021
Q1
$4.86M Buy
44,936
+1,854
+4% +$198K 1.42% 25
2020
Q4
$4.62M Buy
43,082
+5,669
+15% +$545K 1.47% 25
2020
Q3
$3.28M Buy
37,413
+5,627
+18% +$530K 1.31% 26
2020
Q2
$3.12M Buy
31,786
+723
+2% +$63.7K 1.38% 27
2020
Q1
$2.37M Sell
31,063
-4,235
-12% -$361K 1.3% 29
2019
Q4
$3.13M Sell
35,298
-1,334
-4% -$111K 1.28% 29
2019
Q3
$2.77M Sell
36,632
-4,600
-11% -$315K 1.17% 31
2019
Q2
$3M Sell
41,232
-12,559
-23% -$987K 1.28% 27
2019
Q1
$4.33M Sell
53,791
-22,229
-29% -$1.82M 1.95% 18
2018
Q4
$7.01M Sell
76,020
-806
-1% -$70.9K 3.59% 3
2018
Q3
$7.27M Buy
76,826
+1,466
+2% +$139K 2.8% 6
2018
Q2
$6.98M Buy
75,360
+5,722
+8% +$559K 2.89% 4
2018
Q1
$6.59M Sell
69,638
-6,397
-8% -$703K 3.42% 4
2017
Q4
$7.35M Sell
76,035
-5,131
-6% -$484K 2.97% 5
2017
Q3
$7.21M Sell
81,166
-11,660
-13% -$888K 3.03% 3
2017
Q2
$6.73M Sell
92,826
-19,914
-18% -$1.34M 2.73% 9
2017
Q1
$7.35M Sell
112,740
-806
-0.7% -$50.7K 2.7% 6
2016
Q4
$6.88M Buy
113,546
+3,646
+3% +$223K 2.65% 7
2016
Q3
$6.8M Hold
109,900
3.27% 5
2016
Q2
$6.8M Sell
109,900
-5,515
-5% -$336K 3.17% 5
2016
Q1
$6.59M Sell
115,415
-805
-0.7% -$44.9K 3.05% 10
2015
Q4
$6.88M Buy
116,220
+2,004
+2% +$115K 3.27% 7
2015
Q3
$6.21M Sell
114,216
-4,723
-4% -$307K 2.96% 8
2015
Q2
$7.99M Sell
118,939
-6,177
-5% -$403K 3.25% 4
2015
Q1
$7.32M Buy
125,116
+8,231
+7% +$497K 2.96% 8
2014
Q4
$7.65M Sell
116,885
-5,940
-5% -$374K 3.16% 6
2014
Q3
$7.09M Sell
122,825
-10,936
-8% -$607K 3.07% 7
2014
Q2
$7.55M Buy
133,761
+545
+0.4% +$28.6K 3.08% 7
2014
Q1
$6.85M Sell
133,216
-4,475
-3% -$226K 2.97% 8
2013
Q4
$7.27M Sell
137,691
-2,760
-2% -$136K 3.16% 5
2013
Q3
$6.28M Buy
140,451
+4,353
+3% +$193K 3.04% 6
2013
Q2
$5.63M Buy
+136,098
New +$5.95M 2.9% 9

Other funds holding ABBV

SFE Investment Counsel's ABBV Position: Q1 2026 in Review

SFE Investment Counsel reduced its AbbVie (ABBV) stake by 0.38% in Q1 2026, selling an estimated $16.6K and leaving 19,432 shares worth $4.23M. The position accounts for 0.67% of the portfolio, ranked #59.

SFE Investment Counsel first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.99M in Q2 2015. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • SFE Investment Counsel held 19,432 shares of AbbVie worth $4.23M as of Q1 2026.
  • SFE Investment Counsel sold 75 AbbVie shares in Q1 2026, an estimated $16.6K.
  • AbbVie made up 0.67% of SFE Investment Counsel's portfolio in Q1 2026, its #59 holding.
  • SFE Investment Counsel first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • SFE Investment Counsel's AbbVie position peaked at $7.99M in Q2 2015.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on SFE Investment Counsel's 13F filing for Q1 2026, filed 1 May 2026.